Who owns LB PHARMACEUTICALS INC?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of LBRX from SEC Form 13F filings across 147 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 147 institutions disclosed 34.1M shares of LB PHARMACEUTICALS INC worth $1.30B — about 103.1% of shares outstanding; the largest disclosed holder is Deep Track Capital, LP. Source: SEC Form 13F filings, parsed by EvidInvest.
147
13F holders
$1.30B
value, 2026 filers
103.1%
of shares outstanding (34.1M sh)
44
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of LBRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Deep Track Capital, LP | 3.4M | $128.7M | 2.1% | 10.1% | 0.0% |
| 2 | BlackRock, Inc. | 2.3M | $90.1M | 0.0% | 7.1% | -14.2% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 2.2M | $84.8M | 0.9% | 6.7% | 0.0% |
| 4 | Caligan Partners LP | 1.5M | $49.6M | 3.0% | 4.6% | +5.0% |
| 5 | JPMORGAN CHASE & CO | 1.4M | $53.8M | 0.0% | 4.4% | -3.5% |
| 6 | Spruce Street Capital LP | 1.4M | $53.9M | 8.6% | 4.2% | +2.1% |
| 7 | Commodore Capital LP | 1.3M | $49.2M | 3.8% | 3.9% | -14.5% |
| 8 | Trails Edge Capital Partners, LP | 1.1M | $44.1M | 6.3% | 3.5% | -24.5% |
| 9 | FMR LLC | 1.1M | $39.5M | 0.0% | 3.3% | +484.4% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $42.2M | 0.0% | 3.3% | +13.3% |
| 11 | Nantahala Capital Management, LLC | 1.1M | $41.2M | 1.3% | 3.2% | +2.0% |
| 12 | GOLDMAN SACHS GROUP INC | 964,373 | $37.0M | 0.0% | 2.9% | +67.3% |
| 13 | ADAGE CAPITAL PARTNERS GP, L.L.C.NEW | 950,343 | $36.5M | 0.1% | 2.9% | new |
| 14 | Balyasny Asset Management L.P. | 801,521 | $30.8M | 0.0% | 2.4% | -13.0% |
| 15 | Vivo Capital, LLC | 800,000 | $30.7M | 3.4% | 2.4% | 0.0% |
| 16 | Alyeska Investment Group, L.P. | 791,592 | $30.4M | 0.1% | 2.4% | -8.4% |
| 17 | TCG Crossover Management, LLC | 765,050 | $29.4M | 0.8% | 2.3% | -47.1% |
| 18 | FARALLON CAPITAL MANAGEMENT, L.L.C.NEW | 741,410 | $28.5M | 0.1% | 2.2% | new |
| 19 | Bellevue Group AGNEW | 715,513 | $27.5M | 0.6% | 2.2% | new |
| 20 | STATE STREET CORP | 705,405 | $27.1M | 0.0% | 2.1% | +17.2% |
| 21 | Nan Fung Group Holdings Ltd | 630,657 | $24.2M | 16.2% | 1.9% | 0.0% |
| 22 | GEODE CAPITAL MANAGEMENT, LLC | 624,470 | $24.0M | 0.0% | 1.9% | +1.9% |
| 23 | Janus Henderson Group Ltd.NEW | 581,710 | $22.3M | 0.0% | 1.8% | new |
| 24 | JENNISON ASSOCIATES LLC | 576,103 | $22.1M | 0.0% | 1.7% | +6.5% |
| 25 | Integral Health Asset Management, LLC | 470,000 | $18.0M | 1.1% | 1.4% | +213.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.